Kyle A Udd1, Sean Bujarski1, Eric Wirtschafter2, Tanya M Spektor3, Matthew Ghermezi3, Laura Z Rassenti4, Michael E David1, Jason D Nosrati1,5, Ashkon A Rahbari1, James Wang1, Suzie Vardanyan1, Nika M Harutyunyan1, Julia Linesch1, Mingjie Li1, Eric Sanchez1, Haiming Chen1, Thomas J Kipps4, James R Berenson6,7. 1. Institute for Myeloma and Bone Cancer Research, 9201 Sunset Boulevard, Suite 300, West Hollywood, CA, 90069, USA. 2. UCLA-Olive View Medical Center in Sylmar, 14445 Olive View Drive, Sylmar, CA, 91342, USA. 3. Oncotherapeutics, 9201 Sunset Boulevard, Suite 317, West Hollywood, CA, 90069, USA. 4. Moores Cancer Center, University of California at San Diego, 3855 Health Sciences Drive, La Jolla, CA, 92037, USA. 5. College of Human Medicine, Michigan State University, 965 Fee Road A110, East Lansing, MI, 48824, USA. 6. Institute for Myeloma and Bone Cancer Research, 9201 Sunset Boulevard, Suite 300, West Hollywood, CA, 90069, USA. jberenson@imbcr.org. 7. Oncotherapeutics, 9201 Sunset Boulevard, Suite 317, West Hollywood, CA, 90069, USA. jberenson@imbcr.org.
Abstract
BACKGROUND: Chronic lymphocytic leukemia (CLL) is a malignancy of late B cells. In another late B-cell malignancy (multiple myeloma), levels of solubilized B-cell maturation antigen (sBCMA) are elevated and predict outcomes. OBJECTIVE: We sought to evaluate sBCMA as a possible prognostic factor and monitoring tool for patients with CLL. PATIENTS AND METHODS: Using an enzyme-linked immunosorbent assay (ELISA), we assessed plasma (p) levels of BCMA in 171 CLL patients and compared them with levels in healthy individuals. RESULTS: pBCMA levels were significantly higher among patients with CLL than those from healthy donors (p < 0.0001). Among patients with aggressive disease, pBCMA was elevated compared with patients with indolent disease (p < 0.001). Those with an initial pBCMA level in the highest quartile had a shorter time to first treatment compared with CLL patients with pBCMA levels in the lowest three quartiles (p < 0.0001). Among those in the highest quartile (pBCMA > 110.9 ng/mL), overall survival was shorter than those in the lowest three quartiles (p = 0.0007). Finally, among those patients who underwent serial pBCMA testing, changes in these levels correlated with changes in their clinical status. CONCLUSIONS: Together, our findings show that pBCMA is a promising new prognostic and predictive indicator for patients with CLL.
BACKGROUND:Chronic lymphocytic leukemia (CLL) is a malignancy of late B cells. In another late B-cell malignancy (multiple myeloma), levels of solubilized B-cell maturation antigen (sBCMA) are elevated and predict outcomes. OBJECTIVE: We sought to evaluate sBCMA as a possible prognostic factor and monitoring tool for patients with CLL. PATIENTS AND METHODS: Using an enzyme-linked immunosorbent assay (ELISA), we assessed plasma (p) levels of BCMA in 171 CLLpatients and compared them with levels in healthy individuals. RESULTS:pBCMA levels were significantly higher among patients with CLL than those from healthy donors (p < 0.0001). Among patients with aggressive disease, pBCMA was elevated compared with patients with indolent disease (p < 0.001). Those with an initial pBCMA level in the highest quartile had a shorter time to first treatment compared with CLLpatients with pBCMA levels in the lowest three quartiles (p < 0.0001). Among those in the highest quartile (pBCMA > 110.9 ng/mL), overall survival was shorter than those in the lowest three quartiles (p = 0.0007). Finally, among those patients who underwent serial pBCMA testing, changes in these levels correlated with changes in their clinical status. CONCLUSIONS: Together, our findings show that pBCMA is a promising new prognostic and predictive indicator for patients with CLL.
Authors: Tomoyuki Endo; Mitsufumi Nishio; Thomas Enzler; Howard B Cottam; Tetsuya Fukuda; Danelle F James; Michael Karin; Thomas J Kipps Journal: Blood Date: 2006-09-14 Impact factor: 22.113
Authors: Eric Sanchez; Mingjie Li; Alex Kitto; Jennifer Li; Cathy S Wang; Dylan T Kirk; Ori Yellin; Cydney M Nichols; Marissa P Dreyer; Cameryn P Ahles; Austin Robinson; Erik Madden; Gabriel N Waterman; Regina A Swift; Benjamin Bonavida; Ralph Boccia; Robert A Vescio; John Crowley; Haiming Chen; James R Berenson Journal: Br J Haematol Date: 2012-07-18 Impact factor: 6.998
Authors: Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillermo Dighiero; Hartmut Döhner; Peter Hillmen; Michael Keating; Emili Montserrat; Nicholas Chiorazzi; Stephan Stilgenbauer; Kanti R Rai; John C Byrd; Barbara Eichhorst; Susan O'Brien; Tadeusz Robak; John F Seymour; Thomas J Kipps Journal: Blood Date: 2018-03-14 Impact factor: 22.113
Authors: H Döhner; S Stilgenbauer; A Benner; E Leupolt; A Kröber; L Bullinger; K Döhner; M Bentz; P Lichter Journal: N Engl J Med Date: 2000-12-28 Impact factor: 91.245
Authors: Natali Pflug; Jasmin Bahlo; Tait D Shanafelt; Barbara F Eichhorst; Manuela A Bergmann; Thomas Elter; Kathrin Bauer; Gebhart Malchau; Kari G Rabe; Stephan Stilgenbauer; Hartmut Döhner; Ulrich Jäger; Michael J Eckart; Georg Hopfinger; Raymonde Busch; Anna-Maria Fink; Clemens-Martin Wendtner; Kirsten Fischer; Neil E Kay; Michael Hallek Journal: Blood Date: 2014-05-05 Impact factor: 22.113
Authors: William G Wierda; Susan O'Brien; Xuemei Wang; Stefan Faderl; Alessandra Ferrajoli; Kim-Anh Do; Guillermo Garcia-Manero; Jorge Cortes; Deborah Thomas; Charles Koller; Jan Burger; Susan Lerner; Hagop Kantarjian; Michael Keating Journal: J Clin Oncol Date: 2009-02-17 Impact factor: 44.544
Authors: Tatjana Bilich; Annika Nelde; Jens Bauer; Simon Walz; Malte Roerden; Helmut R Salih; Katja Weisel; Britta Besemer; Ana Marcu; Maren Lübke; Juliane Schuhmacher; Marian C Neidert; Hans-Georg Rammensee; Stefan Stevanović; Juliane S Walz Journal: Blood Cancer J Date: 2020-02-28 Impact factor: 11.037